Novartis said to stop work on geographic atrophy gene therapy GT005

11 Sep 2023

Deals

AcquisitionGene TherapyPhase 2

Novartis has halted development of the experimental AAV2-based gene therapy GT005 in geographic atrophy (GA) secondary to dry age-related macular degeneration, Syncona announced Monday. The Swiss drugmaker gained the potential one-time treatment via its purchase of Gyroscope Therapeutics from Syncona in 2022.

According to Syncona, the decision to stop work on GT005 was based on a recommendation from the independent data monitoring committee, which concluded that overall data from the Phase II HORIZON study did not support further development. FirstWord has reached out to Novartis for further details.

The Swiss firm paid $800 million upfront to buy Gyroscope, with the deal also including potential milestone payments of up to $700 million.

More to come.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Novartis AGSyncona Management LLP

Gyroscope Therapeutics Ltd.

[+1]

Indications

Geographic Atrophydry age-related macular degeneration

Targets

Drugs

GT-005

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.